These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32843162)

  • 1. BPI-ANCA is expressed in the airways of cystic fibrosis patients and correlates to platelet numbers and Pseudomonas aeruginosa colonization.
    Hovold G; Lindberg U; Ljungberg JK; Shannon O; Påhlman LI
    Respir Med; 2020; 170():105994. PubMed ID: 32843162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study.
    Lindberg U; Carlsson M; Löfdahl CG; Segelmark M
    Clin Dev Immunol; 2012; 2012():370107. PubMed ID: 23346184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease.
    Carlsson M; Shukla S; Petersson AC; Segelmark M; Hellmark T
    J Cyst Fibros; 2011 Jul; 10(4):265-71. PubMed ID: 21463973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.
    Schultz H; Csernok E; Schuster A; Schmitz TS; Ernst M; Gross WL
    Pediatr Allergy Immunol; 2000 May; 11(2):64-70. PubMed ID: 10893006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies.
    Carlsson M; Eriksson L; Erwander I; Wieslander J; Segelmark M
    Clin Exp Rheumatol; 2003; 21(6 Suppl 32):S95-100. PubMed ID: 14740434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.
    Aichele D; Schnare M; Saake M; Röllinghoff M; Gessner A
    Infect Immun; 2006 Aug; 74(8):4708-14. PubMed ID: 16861658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients.
    Lindberg U; Carlsson M; Hellmark T; Segelmark M
    J Immunol Res; 2015; 2015():947934. PubMed ID: 26273683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis.
    Carlsson M; Eriksson L; Pressler T; Kornfält R; Mared L; Meyer P; Wiik A; Wieslander J; Segelmark M
    J Cyst Fibros; 2007 May; 6(3):228-33. PubMed ID: 17166780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa.
    Sedivá A; Bartůnková J; Bartosová J; Jennette C; Falk RJ; Jethwa HS
    Microbes Infect; 2003 Jan; 5(1):27-30. PubMed ID: 12593970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.
    Mahadeva R; Dunn AC; Westerbeek RC; Sharples L; Whitehouse DB; Carroll NR; Ross-Russell RI; Webb AK; Bilton D; Lomas DA; Lockwood CM
    Clin Exp Immunol; 1999 Sep; 117(3):561-7. PubMed ID: 10469063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive endoscopic image-guided sinus surgery decreases BPI-ANCA in patients with cystic fibrosis.
    Aanaes K; Rasmussen N; Pressler T; Segelmark M; Johansen HK; Lindberg U; Høiby N; Carlsson M; Wieslander J; Buchwald C
    Scand J Immunol; 2012 Dec; 76(6):573-9. PubMed ID: 22946777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociation of systemic and mucosal autoimmunity in cystic fibrosis.
    Theprungsirikul J; Skopelja-Gardner S; Meagher RE; Clancy JP; Zemanick ET; Ashare A; Rigby WFC
    J Cyst Fibros; 2020 Mar; 19(2):196-202. PubMed ID: 31262645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scorpionfish BPI is highly active against multiple drug-resistant
    Holzinger JM; Toelge M; Werner M; Ederer KU; Siegmund HI; Peterhoff D; Blaas SH; Gisch N; Brochhausen C; Gessner A; Bülow S
    Elife; 2023 Jul; 12():. PubMed ID: 37461324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.
    Schultz H; Schinke S; Mosler K; Herlyn K; Schuster A; Gross WL
    Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis.
    Dorlöchter L; Carlsson M; Olafsdottir EJ; Røksund OD; Rosendahl K; Fluge G
    J Cyst Fibros; 2004 Aug; 3(3):179-83. PubMed ID: 15463905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.
    Zhao MH; Jayne DR; Ardiles LG; Culley F; Hodson ME; Lockwood CM
    QJM; 1996 Apr; 89(4):259-65. PubMed ID: 8733512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization.
    Aebi C; Theiler F; Aebischer CC; Schoeni MH
    Pediatr Infect Dis J; 2000 Mar; 19(3):207-12. PubMed ID: 10749460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis.
    Sedivá A; Bartůnková J; Kolárová I; Hrusák O; Vávrová V; Macek M; Lockwood CM; Dunn AC
    J Autoimmun; 1998 Apr; 11(2):185-90. PubMed ID: 9650098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal/Permeability-Increasing Protein Preeminently Mediates Clearance of
    Theprungsirikul J; Skopelja-Gardner S; Burns AS; Wierzbicki RM; Rigby WFC
    Front Immunol; 2021; 12():659523. PubMed ID: 33981306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization.
    Tian Y; Zeng T; Tan L; Wu Y; Yu J; Huang J; Pei Z
    J Clin Lab Anal; 2019 Jul; 33(6):e22908. PubMed ID: 31106488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.